日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models

在小鼠模型中,Kras G12C 和 G12D 驱动的肺癌在致癌效力、免疫原性和 Kras 抑制后的复发方面存在差异。

Huang, Hai-Cheng; Deng, Qing; Guo, Lei; Gorria, Teresa; Pecci, Federica; Yang, Daniella; Rodig, Scott; De Las Casas, Luis; Hallin, Jill; Christensen, James G; Awad, Mark M; Xu, Lin; Ricciuti, Biagio; Akbay, Esra A

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

MTA 协同 PRMT5 抑制剂 BMS-986504 与 KRAS 抑制剂联合使用是治疗 MTAP 缺失 KRAS 突变型胰腺癌的有效策略

Drizyte-Miller, Kristina; Engstrom, Lars D; Klomp, Jeffrey A; Stalnecker, Clint A; Stamey, Addison G; Taylor, Khalilah E; Roach, Mallory K; Robb, Ryan; Waters, Laura M; Calinisan, Andrew; Degan, Seamus; Chang, Wen-Hsuan; Helu, Xousaen M; Nguyen, David; Baldelli, Elisa; Pierobon, Mariaelena; Petricoin, Emanuel F; Briere, David M; Hallin, Jill; Christensen, James G; Bryant, Kirsten L; Cox, Adrienne D; Olson, Peter; Der, Channing J

Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.

KRYSTAL-1 试验中,Adagrasib 治疗非小细胞肺癌患者的共突变和转录特征的影响

Negrao Marcelo V, Paula Alvaro G, Molkentine David, Hover Laura, Nilsson Monique, Vokes Natalie, Engstrom Lars, Calinisan Andrew, Briere David M, Waters Laura, Hallin Jill, Diao Lixia, Altan Mehmet, Blumenschein George R, Skoulidis Ferdinandos, Wang Jing, Kopetz Scott E, Hong David S, Gibbons Don L, Olson Peter, Christensen James G, Heymach John V

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

发现能选择性抑制H1047R PI3Kα突变蛋白的吡啶并嘧啶酮类化合物

Ketcham, John M; Harwood, Stephen J; Aranda, Ruth; Aloiau, Athenea N; Bobek, Briana M; Briere, David M; Burns, Aaron C; Caddell Haatveit, Kersti; Calinisan, Andrew; Clarine, Jeffery; Elliott, Adam; Engstrom, Lars D; Gunn, Robin J; Ivetac, Anthony; Jones, Benjamin; Kuehler, Jon; Lawson, J David; Nguyen, Natalie; Parker, Cody; Pearson, Kelly E; Rahbaek, Lisa; Saechao, Barbara; Wang, Xiaolun; Waters, Anna; Waters, Laura; Watkins, Ashlee H; Olson, Peter; Smith, Christopher R; Christensen, James G; Marx, Matthew A

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

Sitravatinib 用于经分子改变筛选的实体瘤患者:一项 Ib 期研究的结果

Bazhenova, Lyudmila; Kim, Dong-Wan; Cho, Byoung Chul; Goel, Sanjay; Heist, Rebecca; Werner, Theresa L; Eaton, Keith D; Wang, Judy S; Pant, Shubham; Adkins, Douglas R; Blakely, Collin M; Yan, Xiaohong; Neuteboom, Saskia; Christensen, James G; Chao, Richard; Bauer, Todd

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

阿达格拉西布联合或不联合西妥昔单抗治疗KRAS G12C突变型结直肠癌

Yaeger, Rona; Weiss, Jared; Pelster, Meredith S; Spira, Alexander I; Barve, Minal; Ou, Sai-Hong I; Leal, Ticiana A; Bekaii-Saab, Tanios S; Paweletz, Cloud P; Heavey, Grace A; Christensen, James G; Velastegui, Karen; Kheoh, Thian; Der-Torossian, Hirak; Klempner, Samuel J

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases

KRYSTAL-1试验中,Adagrasib对携带KRAS(G12C)突变且伴有未治疗中枢神经系统转移的非小细胞肺癌患者的颅内疗效

Negrao, Marcelo V; Spira, Alexander I; Heist, Rebecca S; Jänne, Pasi A; Pacheco, Jose M; Weiss, Jared; Gadgeel, Shirish M; Velastegui, Karen; Yang, Wenjing; Der-Torossian, Hirak; Christensen, James G; Sabari, Joshua K

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients

循环游离KRAS G12C的早期变化可预测KRAS突变型非小细胞肺癌患者对阿达格拉西布的反应

Paweletz, Cloud P; Heavey, Grace A; Kuang, Yanan; Durlacher, Emily; Kheoh, Thian; Chao, Richard C; Spira, Alexander I; Leventakos, Konstantinos; Johnson, Melissa L; Ou, Sai-Hong Ignatius; Riely, Gregory J; Anderes, Kenna; Yang, Wenjing; Christensen, James G; Jänne, Pasi A

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)

Adagrasib (MRTX849) 治疗晚期 KRAS(G12C) 实体瘤患者的首次人体 I/IB 期剂量探索研究 (KRYSTAL-1)

Ou, Sai-Hong Ignatius; Jänne, Pasi A; Leal, Ticiana A; Rybkin, Igor I; Sabari, Joshua K; Barve, Minal A; Bazhenova, Lyudmila; Johnson, Melissa L; Velastegui, Karen L; Cilliers, Cornelius; Christensen, James G; Yan, Xiaohong; Chao, Richard C; Papadopoulos, Kyriakos P

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Adagrasib (MRTX849) 在脑转移瘤中的活性:KRASG12C 突变型非小细胞肺癌患者的临床前模型和临床数据

Sabari, Joshua K; Velcheti, Vamsidhar; Shimizu, Kazuhide; Strickland, Matthew R; Heist, Rebecca S; Singh, Mohini; Nayyar, Naema; Giobbie-Hurder, Anita; Digumarthy, Subba R; Gainor, Justin F; Rajan, Anant P; Nieblas-Bedolla, Edwin; Burns, Aaron C; Hallin, Jill; Olson, Peter; Christensen, James G; Kurz, Sylvia C; Brastianos, Priscilla K; Wakimoto, Hiroaki